ArticleHIV/AIDS (Auckland, N.Z.)2026
Uptake and Timing of Viral Load Testing and Frequency of Viraemic Episodes During Pregnancy in South Africa.
Article in HIV/AIDS (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Observational
- Uptake and Timing of Viral Load Testing and Frequency of Viraemic Episodes During Pregnancy in South Africa.HIV/AIDS (Auckland, N.Z.) · 2026Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Background: Repeated monitoring of viral load (VL) among pregnant women living with HIV (WLWH) is critical in vertical transmission prevention. For women who are newly diagnosed with HIV during pregnancy, a subsequent VL is recommended three months after ART initiation, and for all women living with HIV, follow-up VL is required every six months throughout pregnancy and breastfeeding. Here, we describe the uptake and timing of VL testing and frequency and distribution of viraemic episodes during pregnancy. Methods: We linked prospective cohort data from WLWH whose infants were born at Rahima Moosa Mother and Child Hospital (RMMCH) in Johannesburg, South Africa (2013-2018) to laboratory data from the National Health Laboratory Services national HIV cohort. We report the uptake and timing of VL testing, and frequency of viremia and viral suppression. We applied the log binomial regression, to explore factors associated with having at least one or more VL test. Crude relative risks (RR) and adjusted relative risks (aRR) with 95% confidence intervals (CI) relative risk were reported. Results: Data from 4064 women with known dates of entry into antenatal care and delivery during the study period were analysed. Overall, less than half (46%) completed VL testing during pregnancy. Most VLs were conducted during the third trimester (67%). Only 5% (n = 100) were during the first trimester and 11% within 7 days of delivery. Three-quarters of tests during pregnancy indicated viral suppression (VL < 400 copies/mL), 7% viraemic (VL 400-1000 copies/mL), and 19% high-grade viraemia (VL > 1000 copies/mL). We found that being older (≥35) and being engaged in HIV care prior to pregnancy were significantly associated with VL testing during pregnancy. Conclusion: With less than half of pregnant women living with HIV in this study having a VL measure during their pregnancy, and VL testing occurring late in pregnancy, this study highlights critical gaps in providing quality HIV care to women and prevention of vertical transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.